RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Rani Therapeutics Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.65+0.01 (+1.51%)
Close on Oct 19, 2026
- Market cap
- $121.72M
- P/E (TTM)
- –
- Dividend yield
- –
Rani Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Rani Therapeutics | Industry median |
|---|---|---|
| Market Cap | $90.65M | $197.05M |
| Enterprise Value | $94.53M | $106.56M |
| PS Ratio | 18.59 | 3.93 |
| PB Ratio | 2.31 | 2.14 |
| P/TBV Ratio | 2.31 | 2.46 |
Enterprise value
| Measure | Rani Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 19.38 | 2.69 |
Income (trailing twelve months)
| Measure | Rani Therapeutics | Industry median |
|---|---|---|
| Revenue | $4.88M | $57.94M |
| Operating Income | -$32.96M | -$21.44M |
| Net Income | -$30.14M | -$22.46M |
| EBITDA | -$32.24M | -$16.91M |
Margins
| Measure | Rani Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -675.8% | -44.5% |
| Profit Margin | -618.0% | -39.2% |
| EBITDA Margin | -661.0% | -31.3% |
| FCF Margin | -417.0% | -8.85% |
Returns
| Measure | Rani Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -179.1% | -53.1% |
| Return on Assets (ROA) | -77.5% | -41.0% |
| Return on Invested Capital (ROIC) | -145.4% | -32.0% |
| Return on Capital Employed (ROCE) | -65.6% | -37.8% |
Growth
| Measure | Rani Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 306.4% | 6.01% |
| Revenue Growth (5Y CAGR) | 28.7% | 6.42% |
Balance sheet
| Measure | Rani Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $4.87M | $62.42M |
| Net Cash (Debt) | $4.87M | $15.68M |
| Net Cash Per Share | $0.03 | $0.65 |
| Equity (Book Value) | $39.23M | $48.79M |
| Book Value Per Share | $0.28 | $1.36 |
| Tangible Book Value | $39.23M | $23.06M |
| Working Capital | $45.89M | $75.77M |
Financial position
| Measure | Rani Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 5.31 | 3.30 |
| Quick Ratio | 0.65 | 2.39 |
| Interest Coverage | -28.22 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Rani Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$20.29M | -$12.35M |
| Capital Expenditures | -$47.00K | -$1.06M |
| Free Cash Flow | -$20.34M | -$20.28M |
| FCF Per Share | -$0.15 | -$0.41 |
Efficiency
| Measure | Rani Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.13 | 0.38 |
| Revenue Per Employee | $70.68K | $398.96K |
| Profits Per Employee | -$436.83K | -$732.08K |
| Employee Count | 69 | 73 |
Dividends and yields
| Measure | Rani Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -33.3% | -21.2% |
| FCF Yield | -22.4% | -7.64% |
Shares
| Measure | Rani Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 139,395,000 | 59,128,900 |
| Float | 96,770,400 | 48,744,500 |
| Shares Held by Insiders | 30.6% | 11.8% |
| Shares Held by Institutions | 32.7% | 59.4% |
Scores
| Measure | Rani Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 0.04 | 0.10 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Rani Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.